Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v4-FR | Version v3-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2024-01-31 | 2024-01-31 |
| Drug Identification Number | 02236926 | 02236926 |
| Brand name | ACYCLOVIR SODIUM INJECTION | ACYCLOVIR SODIUM INJECTION |
| Common or Proper name | ACYCLOVIR SODIUM INJECTION | ACYCLOVIR SODIUM INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | ACYCLOVIR | ACYCLOVIR |
| Strength(s) | 50MG | 50MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 20 mL | 20 mL |
| ATC code | J05AB | J05AB |
| ATC description | DIRECT ACTING ANTIVIRALS | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-12-15 | 2023-12-15 |
| Actual start date | 2023-12-15 | 2023-12-15 |
| Estimated end date | 2024-03-01 | 2024-03-01 |
| Actual end date | 2024-01-29 | 2024-01-29 |
| Shortage status | Resolved | Resolved |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Acyclovir Sodium Injection 50 mg/mL SD Vial 20 mL effective December 15, 2023, until March 1, 2024. Effective December 1, 2023, allocations for our Acyclovir Sodium Injection 50 mg/mL SD Vial 10 mL will be increased to cover 100% of historical monthly demand of the 10 mL plus 100% of historical monthly demand of the 20 mL at a 2:1 ratio. | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Acyclovir Sodium Injection 50 mg/mL SD Vial 20 mL effective December 15, 2023, until March 1, 2024. Effective December 1, 2023, allocations for our Acyclovir Sodium Injection 50 mg/mL SD Vial 10 mL will be increased to cover 100% of historical monthly demand of the 10 mL plus 100% of historical monthly demand of the 20 mL at a 2:1 ratio. |
| Health Canada comments |